Erudio Healtherudio.com
Indication
Medullary thyroid cancer trials: what clinicians said in public
No HCP commentary report on a trial in medullary thyroid cancer yet. Erudio has found public clinician commentary on 5 clinical trials in medullary thyroid cancer, including ARROW, EXAM, LIBRETTO-001 and LIBRETTO-531. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| LIBRETTO-001 NCT03157128 · Eli Lilly and Company DeepView → | RET-activated advanced solid tumors | Phase 1/Phase 2 | Deep | View | |||
| LIBRETTO-531 NCT04211337 · Loxo Oncology, Inc. DeepView → | kinase inhibitor-naïve advanced RET-mutant medullary thyroid cancer | Phase 3 | Deep | View | |||
| ARROW NCT03037385 · Hoffmann-La Roche FocusedView → | Not given | Phase 1/Phase 2 | Focused | View | |||
| EXAM NCT00704730 · Exelixis FocusedView → | unresectable, locally advanced or metastatic medullary thyroid cancer | Phase 3 | Focused | View | |||
| LIBRETTO-121 NCT03899792 · Eli Lilly and Company FocusedView → | pediatric advanced RET-altered solid or primary CNS tumors | Phase 1/Phase 2 | Focused | View | |||